Literature DB >> 32064106

Outcome of patients with lung cancer and severe psychiatric disorder admitted to a medical psychiatric unit.

Tomohiro Takehara1,2, Tetsuo Tani2, Hiroyuki Takiue3, Ryo Takeshita2, Arifumi Iwamaru4, Tatsuya Yamamoto4, Hidefumi Koh2.   

Abstract

The purpose of the present study was to evaluate the clinical profiles and treatment outcomes of patients with lung cancer admitted to the Medical Psychiatric Unit (MPU), which is built for patients with physical and severe psychiatric disorders. All medical records of patients with lung cancer admitted to the MPU of Tachikawa hospital were reviewed. The clinical outcomes of these patients were retrospectively evaluated between January 2010 and December 2016. A total of 24 patients in the MPU were histologically or cytologically diagnosed with primary lung cancer. Of these, 20 patients had schizophrenia, and 4 patients had a mood disorder. There were 15 patients who were diagnosed using bronchoscopy. The histology indicated adenocarcinoma, squamous cell carcinoma and non-small-cell lung cancer-not otherwise specified were in 11, 8, and 1 patient, respectively, while small-cell lung cancer was indicated in 4 patients. Surgery, chemoradiotherapy, radiotherapy, chemotherapy was performed in 13, 4, 2, 1 and 4 patients, respectively. The median survival time was 76.7 months for patients who underwent surgery, while it was 14.4 months for those who underwent chemoradiotherapy. In the MPU, patients with lung cancer and severe psychiatric disorders could be safely diagnosed, and patients with early-stage lung cancer exhibited long-term survival.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  lung cancer; medical psychiatric unit; mood disorder; psychiatric disorder; schizophrenia

Year:  2020        PMID: 32064106      PMCID: PMC7016514          DOI: 10.3892/mco.2020.1974

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  15 in total

1.  Reducing smoking among psychiatric inpatients: a survey of psychiatrists.

Authors:  L Landow; B Szetela; M A Know
Journal:  Am J Public Health       Date:  1995-08       Impact factor: 9.308

2.  Outcome after lung cancer surgery. Factors predicting early mortality and major morbidity.

Authors:  G Myrdal; G Gustafsson; M Lambe; L G Hörte; E Ståhle
Journal:  Eur J Cardiothorac Surg       Date:  2001-10       Impact factor: 4.191

3.  A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors.

Authors:  Jose de Leon; Francisco J Diaz
Journal:  Schizophr Res       Date:  2005-07-15       Impact factor: 4.939

4.  Diffusing capacity predicts morbidity after lung resection in patients without obstructive lung disease.

Authors:  Mark K Ferguson; Wickii T Vigneswaran
Journal:  Ann Thorac Surg       Date:  2008-04       Impact factor: 4.330

5.  Outcomes of surgery in lung cancer patients with schizophrenia.

Authors:  Toshiro Obuchi; Kan Okabayashi; Takayuki Imakiire; Satoshi Yoneda; Akinori Iwasaki
Journal:  Surg Today       Date:  2013-04-18       Impact factor: 2.549

6.  Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis.

Authors:  V S Catts; S V Catts; B I O'Toole; A D J Frost
Journal:  Acta Psychiatr Scand       Date:  2008-03-10       Impact factor: 6.392

7.  The medical-psychiatric unit: a novel psychosomatic approach.

Authors:  G A Fava; T N Wise; G Molnar; M Zielezny
Journal:  Psychother Psychosom       Date:  1985       Impact factor: 17.659

8.  Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Alessandro Brunelli; Anthony W Kim; Kenneth I Berger; Doreen J Addrizzo-Harris
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

9.  Do patients with schizophrenia receive state-of-the-art lung cancer therapy? A brief report.

Authors:  Farrah J Mateen; Aminah Jatoi; Timothy W Lineberry; Dawn Aranguren; Edward T Creagan; Gary A Croghan; James R Jett; Randolph S Marks; Julian R Molina; Ronald L Richardson
Journal:  Psychooncology       Date:  2008-07       Impact factor: 3.894

Review 10.  Therapeutic management options for stage III non-small cell lung cancer.

Authors:  Stephanie M Yoon; Talha Shaikh; Mark Hallman
Journal:  World J Clin Oncol       Date:  2017-02-10
View more
  1 in total

1.  Palliative and high-intensity end-of-life care in schizophrenia patients with lung cancer: results from a French national population-based study.

Authors:  Marie Viprey; Vanessa Pauly; Sebastien Salas; Karine Baumstarck; Veronica Orleans; Pierre-Michel Llorca; Christophe Lancon; Pascal Auquier; Laurent Boyer; Guillaume Fond
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-09-02       Impact factor: 5.270

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.